PMID- 12563241
OWN - NLM
STAT- MEDLINE
DCOM- 20030318
LR  - 20220409
IS  - 0039-6060 (Print)
IS  - 0039-6060 (Linking)
VI  - 133
IP  - 1
DP  - 2003 Jan
TI  - Mammaglobin-A is a tumor-associated antigen in human breast carcinoma.
PG  - 74-80
AB  - BACKGROUND: Mammaglobin-A is an attractive target for immune-based therapy for 
      patients with breast cancer because of its exclusive expression in breast cancer. 
      In this study, we attempted to identify immunogenic T cell epitopes restricted by 
      human leukocyte antigen (HLA)-A2 in mammaglobin-A protein. METHODS: To identify 
      HLA-A2-restricted immunogenic epitopes from mammaglobin-A, 7 candidate peptides 
      were synthesized and tested for immunogenicity. Each peptide was tested for 
      binding to HLA-A2 in a HLA-A2 stabilization assay. Furthermore, T lymphocytes 
      from 7 healthy donors and 1 patient with breast cancer received 3 weekly 
      stimulations with autologous peptide-pulsed dendritic cells. Stimulated T cells 
      were tested for specific recognition of peptide and tumor cells by 
      interferon-gamma enzyme-linked immunosorbent assay. RESULTS: HLA-A2 binding 
      assays showed that all designed peptides could bind to HLA-A2. Two of the 7 
      peptides (MAM3 and MAM7) successfully induced peptide-specific T cells. However, 
      only MAM3-specific T cells recognized the mammaglobin overexpressing breast 
      cancer cell line, MDA415 transfected with HLA-A2. In contrast, MAM3-specific T 
      cell did not recognize wild type MDA415 or MDA415 transfected with HLA-A24, or 
      the mammaglobin negative, HLA-A2 positive breast cancer cell line, MCF-7. 
      CONCLUSIONS: Mammaglobin-A-derived peptide, MAM3, can induce 
      mammaglobin-A-specific immunity and could be useful for vaccine strategies for 
      patients with breast cancer.
FAU - Tanaka, Yoshiyuki
AU  - Tanaka Y
AD  - Washington University School of Medicine, Department of Surgery, St Louis, Mo 
      63110, USA.
FAU - Amos, Keith D
AU  - Amos KD
FAU - Fleming, Timothy P
AU  - Fleming TP
FAU - Eberlein, Timothy J
AU  - Eberlein TJ
FAU - Goedegebuure, Peter S
AU  - Goedegebuure PS
LA  - eng
GR  - R01 CA68500/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Surgery
JT  - Surgery
JID - 0417347
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (Epitopes)
RN  - 0 (HLA-A2 Antigen)
RN  - 0 (Mammaglobin A)
RN  - 0 (Neoplasm Proteins)
RN  - 0 (Peptide Fragments)
RN  - 0 (SCGB2A2 protein, human)
RN  - 9060-09-7 (Uteroglobin)
SB  - IM
MH  - Antigens, Neoplasm/*immunology/metabolism
MH  - Breast Neoplasms/*diagnosis/*immunology
MH  - Cells, Cultured
MH  - Epitopes/immunology/metabolism
MH  - Female
MH  - Flow Cytometry
MH  - HLA-A2 Antigen/metabolism
MH  - Humans
MH  - Immunotherapy
MH  - Mammaglobin A
MH  - Neoplasm Proteins/*immunology/metabolism
MH  - Peptide Fragments/immunology/metabolism
MH  - T-Lymphocytes/immunology
MH  - Uteroglobin/*immunology/metabolism
EDAT- 2003/02/04 04:00
MHDA- 2003/03/19 04:00
CRDT- 2003/02/04 04:00
PHST- 2003/02/04 04:00 [pubmed]
PHST- 2003/03/19 04:00 [medline]
PHST- 2003/02/04 04:00 [entrez]
AID - S003960600221692X [pii]
AID - 10.1067/msy.2003.92 [doi]
PST - ppublish
SO  - Surgery. 2003 Jan;133(1):74-80. doi: 10.1067/msy.2003.92.